ß-Lactam allergy delabeling is safe and saves costs in Primary Care.
Aten Primaria
; 56(11): 102925, 2024 May 24.
Article
em En
| MEDLINE
| ID: mdl-38795675
ABSTRACT
OBJECTIVE:
To determine whether the ß-lactam allergy delabeling was safe and cost-saving in Primary Care (PC) patients.DESIGN:
We have conducted a retrospective chart review of PC patients with ß-lactam allergy label evaluated in our Allergy Unit between 2017 and 2022. SITE Allergy Department. Hospital Virgen del Rocio (Sevilla).PARTICIPANTS:
A total of 391 patients labeled for ß-lactam allergy in PC were studied. MAIN MEASUREMENTS (a) Outcome evaluation of a ß-lactam allergy delabeling procedure. (b) A ratio between the total e-prescribed antibiotic cost and the number of treatment days (the experimental daily antibiotic cost or EDAC) before and after delabeling was analyzed in delabeled and truly allergic patients.RESULTS:
The results of skin testing were positive in 9.2% of the reported cases (36 of 391 patients). The reactions to oral provocation challenge (OPC) occurred in 2.14% of the patients who underwent negative skin testing to offending ß-lactam (in 15 of 699 OPC). A total of 307 patients (78.5%) were delabeled; 70 (17.9%) had a ß-lactam selective response and 14 (3.59%) reacted to both penicillin and cephalosporin. The EDAC before and after the procedure in delabeled patients was significantly lower (0.88 vs 0.62 , p<10-3), than that observed in truly allergic group (0.87 vs. 0.76 , p=not significant).CONCLUSION:
To delabel ß-lactam allergy in Primary Care patients is safe in most patients, cost-saving in antibioticotherapy, and allows identify the main clinical ß-lactam allergy phenotypes that benefit from this procedure.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article